{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T23:38:02Z","timestamp":1769557082947,"version":"3.49.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,7,24]],"date-time":"2018-07-24T00:00:00Z","timestamp":1532390400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Medical Talents Training Program of Health and Family Planning Commission of Fujian Province","award":["2016-ZQN-34"],"award-info":[{"award-number":["2016-ZQN-34"]}]},{"name":"Medical Center of Minimally Invasive Technology of Fujian Province","award":["No. 171, 2017 and No. 4, 2017"],"award-info":[{"award-number":["No. 171, 2017 and No. 4, 2017"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13046-018-0848-6","type":"journal-article","created":{"date-parts":[[2018,7,24]],"date-time":"2018-07-24T08:05:44Z","timestamp":1532419544000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["WIPF1 antagonizes the tumor suppressive effect of miR-141\/200c and is associated with poor survival in patients with PDAC"],"prefix":"10.1186","volume":"37","author":[{"given":"Yu","family":"Pan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengchun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maoen","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheyang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianchao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minggui","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heguang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,7,24]]},"reference":[{"issue":"4","key":"848_CR1","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3322\/caac.21349","volume":"66","author":"KD Miller","year":"2016","unstructured":"Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66(4):271\u201389.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"848_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7\u201330.","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"848_CR3","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1002\/cncr.26553","volume":"118","author":"SC Mayo","year":"2012","unstructured":"Mayo SC, Nathan H, Cameron JL, Olino K, Edil BH, Herman JM, et al. Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent. Cancer. 2012;118(10):2674\u201381.","journal-title":"Cancer"},{"issue":"4","key":"848_CR4","doi-asserted-by":"publisher","first-page":"e1000267","DOI":"10.1371\/journal.pmed.1000267","volume":"7","author":"S Gillen","year":"2010","unstructured":"Gillen S, Schuster T, B\u00fcschenfelde CMZ, Friess H, Kleeff J. Preoperative\/neoadjuvant therapy in pancreatic Cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7(4):e1000267.","journal-title":"PLoS Med"},{"issue":"6","key":"848_CR5","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/nrclinonc.2013.66","volume":"10","author":"J Werner","year":"2013","unstructured":"Werner J, Combs SE, Springfeld C, Hartwig W, Hackert T, B\u00fcchler MW. Advanced-stage pancreatic cancer: therapy options. Nat Rev Clin Oncol. 2013;10(6):323.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"848_CR6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/jhg.2016.59","volume":"62","author":"K Yonemori","year":"2017","unstructured":"Yonemori K, Kurahara H, Maemura K, Natsugoe S. MicroRNA in pancreatic cancer. J Hum Genet. 2017;62(1):33\u201340.","journal-title":"J Hum Genet"},{"issue":"6","key":"848_CR7","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.molonc.2012.07.007","volume":"6","author":"H Suzuki","year":"2012","unstructured":"Suzuki H, Maruyama R, Yamamoto E, Kai M. DNA methylation and microRNA dysregulation in cancer. Mol Oncol. 2012;6(6):567\u201378.","journal-title":"Mol Oncol"},{"issue":"13","key":"848_CR8","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1002\/pros.23201","volume":"76","author":"SM Lynch","year":"2016","unstructured":"Lynch SM, O'Neill KM, McKenna MM, Walsh CP, McKenna DJ. Regulation of miR-200c and miR-141 by methylation in prostate Cancer. Prostate. 2016;76(13):1146\u201359.","journal-title":"Prostate"},{"issue":"1","key":"848_CR9","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1007\/s12032-014-0428-3","volume":"32","author":"X Zhou","year":"2014","unstructured":"Zhou X, Wang Y, Shan B, Han J, Zhu H, Lv Y, et al. The downregulation of miR-200c\/141 promotes ZEB1\/2 expression and gastric cancer progression. Med Oncol. 2014;32(1):428.","journal-title":"Med Oncol"},{"issue":"14","key":"848_CR10","doi-asserted-by":"crossref","first-page":"18684","DOI":"10.18632\/oncotarget.7629","volume":"7","author":"W Wu","year":"2016","unstructured":"Wu W, Sun H, Zhang R, Yu X, Shi X, Zhu M, et al. Methylation-associated silencing of miR-200b facilitates human hepatocellular carcinoma progression by directly targeting BMI1. Oncotarget. 2016;7(14):18684\u201393.","journal-title":"Oncotarget"},{"issue":"4","key":"848_CR11","doi-asserted-by":"publisher","first-page":"879","DOI":"10.3892\/ijmm.2014.1625","volume":"33","author":"S Tamagawa","year":"2014","unstructured":"Tamagawa S, Beder LB, Hotomi M, Gunduz M, Yata K, Grenman R, et al. Role of miR-200c\/miR-141 in the regulation of epithelial-mesenchymal transition and migration in head and neck squamous cell carcinoma. Int J Mol Med. 2014;33(4):879\u201386.","journal-title":"Int J Mol Med"},{"issue":"30","key":"848_CR12","doi-asserted-by":"publisher","first-page":"4297","DOI":"10.1038\/onc.2010.201","volume":"29","author":"S Uhlmann","year":"2010","unstructured":"Uhlmann S, Zhang JD, Schw\u00e4ger A, Mannsperger H, Riazalhosseini Y, Burmester S, et al. miR-200bc\/429 cluster targets PLCgamma1 and differentially regulates proliferation and EGF-driven invasion than miR-200a\/141 in breast cancer. Oncogene. 2010;29(30):4297\u2013306.","journal-title":"Oncogene"},{"issue":"3","key":"848_CR13","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.cell.2009.07.011","volume":"138","author":"Y Shimono","year":"2009","unstructured":"Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D, et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell. 2009;138(3):592\u2013603.","journal-title":"Cell"},{"issue":"13","key":"848_CR14","doi-asserted-by":"publisher","first-page":"5226","DOI":"10.1158\/0008-5472.CAN-09-4227","volume":"70","author":"A Li","year":"2010","unstructured":"Li A, Omura N, Hong SM, Vincent A, Walter K, Griffith M, et al. Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a\/200b in association with elevated circulating miR-200a and miR-200b levels. Cancer Res. 2010;70(13):5226\u201337.","journal-title":"Cancer Res"},{"issue":"1","key":"848_CR15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.tranon.2015.11.005","volume":"9","author":"X Wu","year":"2016","unstructured":"Wu X, Wu G, Wu Z, Yao X, Li G. MiR-200a suppresses the proliferation and metastasis in pancreatic ductal adenocarcinoma through downregulation of DEK gene. Transl Oncol. 2016;9(1):25\u201331.","journal-title":"Transl Oncol"},{"issue":"2","key":"848_CR16","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3892\/ijo.2013.2189","volume":"44","author":"L Xu","year":"2014","unstructured":"Xu L, Li Q, Xu D, Wang Q, An Y, Du Q, et al. hsa-miR-141 downregulates TM4SF1 to inhibit pancreatic cancer cell invasion and migration. Int J Oncol. 2014;44(2):459\u201366.","journal-title":"Int J Oncol"},{"issue":"1\u20132","key":"848_CR17","first-page":"39","volume":"388","author":"Z-M Zhu","year":"2013","unstructured":"Zhu Z-M, Xu Y-F, Su Q-J, Du J-D, Tan X-L, Tu Y-L, et al. Prognostic significance of microRNA-141 expression and its tumor suppressor function in human pancreatic ductal adenocarcinoma. Mol Cell Biochem. 2013;388(1\u20132):39\u201349.","journal-title":"Mol Cell Biochem"},{"issue":"10","key":"848_CR18","doi-asserted-by":"publisher","first-page":"e73356","DOI":"10.1371\/journal.pone.0073356","volume":"8","author":"P Radhakrishnan","year":"2013","unstructured":"Radhakrishnan P, Mohr AM, Grandgenett PM, Steele MM, Batra SK, Hollingsworth MA. MicroRNA-200c modulates the expression of MUC4 and MUC16 by directly targeting their coding sequences in human pancreatic cancer. PLoS One. 2013;8(10):e73356.","journal-title":"PLoS One"},{"issue":"1","key":"848_CR19","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/S0955-0674(01)00297-6","volume":"14","author":"DA Schafer","year":"2002","unstructured":"Schafer DA. Coupling actin dynamics and membrane dynamics during endocytosis. Curr Opin Cell Biol. 2002;14(1):76.","journal-title":"Curr Opin Cell Biol"},{"issue":"5","key":"848_CR20","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1242\/jcs.093799","volume":"125","author":"RP Stevenson","year":"2012","unstructured":"Stevenson RP, Veltman D, Machesky LM. Actin-bundling proteins in cancer progression at a glance. J Cell Sci. 2012;125(5):1073\u20139.","journal-title":"J Cell Sci"},{"issue":"11","key":"848_CR21","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.cub.2013.04.051","volume":"23","author":"SK Donnelly","year":"2013","unstructured":"Donnelly SK, Weisswange I, Zettl M, Way M. WIP provides an essential link between Nck and N-WASP during Arp2\/3-dependent actin polymerization. Curr Biol. 2013;23(11):999\u20131006.","journal-title":"Curr Biol"},{"issue":"1","key":"848_CR22","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1084\/jem.20110896","volume":"209","author":"G Lanzi","year":"2012","unstructured":"Lanzi G, Moratto D, Vairo D, Masneri S, Delmonte O, Paganini T, et al. A novel primary human immunodeficiency due to deficiency in the WASP-interacting protein WIP. J Exp Med. 2012;209(1):29\u201334.","journal-title":"J Exp Med"},{"issue":"2","key":"848_CR23","first-page":"243","volume":"2","author":"R Rengan","year":"2000","unstructured":"Rengan R, Ochs HD. Molecular biology of the Wiskott-Aldrich syndrome. Rev Immunogenet. 2000;2(2):243\u201355.","journal-title":"Rev Immunogenet"},{"issue":"6 Pt 1","key":"848_CR24","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/S0022-3476(05)82002-5","volume":"125","author":"KE Sullivan","year":"1994","unstructured":"Sullivan KE, Mullen CA, Blaese RM, Winkelstein JA. A multiinstitutional survey of the Wiskott-Aldrich syndrome. J Pediatr. 1994;125(6 Pt 1):876\u201385.","journal-title":"J Pediatr"},{"issue":"6","key":"848_CR25","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s00109-009-0467-y","volume":"87","author":"E Staub","year":"2009","unstructured":"Staub E, Groene J, Heinze M, Mennerich D, Roepcke S, Klaman I, et al. An expression module of WIPF1-coexpressed genes identifies patients with favorable prognosis in three tumor types. J Mol Med. 2009;87(6):633\u201344.","journal-title":"J Mol Med"},{"issue":"4","key":"848_CR26","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1101\/gad.210773.112","volume":"27","author":"FX Yu","year":"2013","unstructured":"Yu FX, Guan KL. The hippo pathway: regulators and regulations. Genes Dev. 2013;27(4):355\u201371.","journal-title":"Genes Dev"},{"issue":"21","key":"848_CR27","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1101\/gad.1602907","volume":"21","author":"B Zhao","year":"2007","unstructured":"Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, et al. Inactivation of YAP oncoprotein by the hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 2007;21(21):2747\u201361.","journal-title":"Genes Dev"},{"issue":"19","key":"848_CR28","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1101\/gad.197582.112","volume":"26","author":"JS Mo","year":"2012","unstructured":"Mo JS, Yu FX, Gong R, Brown JH, Guan KL. Regulation of the hippo-YAP pathway by protease-activated receptors (PARs). Genes Dev. 2012;26(19):2138\u201343.","journal-title":"Genes Dev"},{"issue":"4","key":"848_CR29","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.cell.2011.09.048","volume":"147","author":"M Cordenonsi","year":"2011","unstructured":"Cordenonsi M, Zanconato F, Azzolin L, Forcato M, Rosato A, Frasson C, et al. The hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell. 2011;147(4):759\u201372.","journal-title":"Cell"},{"issue":"4","key":"848_CR30","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1152\/physrev.00005.2014","volume":"94","author":"S Piccolo","year":"2014","unstructured":"Piccolo S, Dupont S, Cordenonsi M. The biology of YAP\/TAZ: hippo signaling and beyond. Physiol Rev. 2014;94(4):1287\u2013312.","journal-title":"Physiol Rev"},{"issue":"8","key":"848_CR31","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1038\/bjc.2015.102","volume":"112","author":"Z Zhu","year":"2015","unstructured":"Zhu Z, Xu Y, Zhao J, Liu Q, Feng W, Fan J, et al. miR-367 promotes epithelial-to-mesenchymal transition and invasion of pancreatic ductal adenocarcinoma cells by targeting the Smad7-TGF-beta signalling pathway. Br J Cancer. 2015;112(8):1367\u201375.","journal-title":"Br J Cancer"},{"issue":"8","key":"848_CR32","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1016\/j.celrep.2016.10.064","volume":"17","author":"R Gargini","year":"2016","unstructured":"Gargini R, Escoll M, Garcia E, Garcia-Escudero R, Wandosell F, Anton IM. WIP drives tumor progression through YAP\/TAZ-dependent autonomous cell growth. Cell Rep. 2016;17(8):1962\u201377.","journal-title":"Cell Rep"},{"key":"848_CR33","doi-asserted-by":"crossref","unstructured":"Zeng Y, Yi R, Cullen BR. MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms. Proc Natl Acad Sci U S A. 2003;100(17):9779\u201384.","DOI":"10.1073\/pnas.1630797100"},{"issue":"2","key":"848_CR34","doi-asserted-by":"publisher","first-page":"e55910","DOI":"10.1371\/journal.pone.0055910","volume":"8","author":"L Cascione","year":"2013","unstructured":"Cascione L, Gasparini P, Lovat F, Carasi S, Pulvirenti A, Ferro A, et al. Integrated microRNA and mRNA signatures associated with survival in triple negative breast cancer. PLoS One. 2013;8(2):e55910.","journal-title":"PLoS One"},{"key":"848_CR35","doi-asserted-by":"crossref","unstructured":"Tejero R, Navarro A, Campayo M, Vinolas N, Marrades RM, Cordeiro A, et al. miR-141 and miR-200c as markers of overall survival in early stage non-small cell lung cancer adenocarcinoma. PLoS One. 2014;9(7):e101899.","DOI":"10.1371\/journal.pone.0101899"},{"issue":"10","key":"848_CR36","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1158\/1078-0432.CCR-13-3224","volume":"20","author":"X Chen","year":"2014","unstructured":"Chen X, Wang X, Ruan A, Han W, Zhao Y, Lu X, et al. miR-141 is a key regulator of renal cell carcinoma proliferation and metastasis by controlling EphA2 expression. Clin Cancer Res. 2014;20(10):2617\u201330.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"848_CR37","doi-asserted-by":"publisher","first-page":"e73306","DOI":"10.1371\/journal.pone.0073306","volume":"8","author":"AM Mohr","year":"2013","unstructured":"Mohr AM, Bailey JM, Lewallen ME, Liu X, Radhakrishnan P, Yu F, et al. MUC1 regulates expression of multiple microRNAs involved in pancreatic tumor progression, including the miR-200c\/141 cluster. PLoS One. 2013;8(10):e73306.","journal-title":"PLoS One"},{"key":"848_CR38","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/1476-4598-9-169","volume":"9","author":"J Yu","year":"2010","unstructured":"Yu J, Ohuchida K, Mizumoto K, Sato N, Kayashima T, Fujita H, et al. MicroRNA, hsa-miR-200c, is an independent prognostic factor in pancreatic cancer and its upregulation inhibits pancreatic cancer invasion but increases cell proliferation. Mol Cancer. 2010;9:169.","journal-title":"Mol Cancer"},{"issue":"1","key":"848_CR39","doi-asserted-by":"crossref","first-page":"900","DOI":"10.18632\/oncotarget.13400","volume":"8","author":"T Zhang","year":"2017","unstructured":"Zhang T, Shen X, Liu R, Zhu G, Bishop J, Xing M. Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness. Oncotarget. 2017;8(1):900\u201314.","journal-title":"Oncotarget"},{"issue":"7","key":"848_CR40","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.semcdb.2012.05.004","volume":"23","author":"W Hong","year":"2012","unstructured":"Hong W, Guan KL. The YAP and TAZ transcription co-activators: key downstream effectors of the mammalian hippo pathway. Semin Cell Dev Biol. 2012;23(7):785\u201393.","journal-title":"Semin Cell Dev Biol"},{"issue":"4","key":"848_CR41","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/nrc3458","volume":"13","author":"KF Harvey","year":"2013","unstructured":"Harvey KF, Zhang X, Thomas DM. The hippo pathway and human cancer. Nat Rev Cancer. 2013;13(4):246\u201357.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"848_CR42","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1242\/dev.045500","volume":"138","author":"G Halder","year":"2011","unstructured":"Halder G, Johnson RL. Hippo signaling: growth control and beyond. Development. 2011;138(1):9\u201322.","journal-title":"Development"},{"issue":"1","key":"848_CR43","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.cell.2014.06.013","volume":"158","author":"L Azzolin","year":"2014","unstructured":"Azzolin L, Panciera T, Soligo S, Enzo E, Bicciato S, Dupont S, et al. YAP\/TAZ incorporation in the beta-catenin destruction complex orchestrates the Wnt response. Cell. 2014;158(1):157\u201370.","journal-title":"Cell"},{"issue":"1","key":"848_CR44","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.devcel.2016.03.002","volume":"37","author":"MJ Oudhoff","year":"2016","unstructured":"Oudhoff MJ, Braam MJS, Freeman SA, Wong D, Rattray DG, Wang J, et al. SETD7 controls intestinal regeneration and tumorigenesis by regulating Wnt\/beta-catenin and hippo\/YAP signaling. Dev Cell. 2016;37(1):47\u201357.","journal-title":"Dev Cell"}],"container-title":["Journal of Experimental & Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-018-0848-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13046-018-0848-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-018-0848-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T15:12:06Z","timestamp":1604675526000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-018-0848-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,24]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["848"],"URL":"https:\/\/doi.org\/10.1186\/s13046-018-0848-6","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,24]]},"assertion":[{"value":"14 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Animal experiment protocols were approved by the Ethics Committee for Animal Research of Fuzhou General Hospital of Chinese PLA Nanjing Military Command. (No. FZZY-2016-26). All patients whose tissue samples were used in this research provided written informed consent, and the study protocol was approved by the Committee for the Ethical Review of Research, Fujian Medical University Union Hospital (No. 2016-ZQN-34).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable in this section.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"167"}}